Nuo Therapeutics (AURX) Stock Analysis & Winston Score

Nuo Therapeutics is a small medical device company that makes a wound-care system called MIST Therapy — wait, actually its core product is the Aurix System, which uses a patient's own blood to help heal chronic wounds. The company sells primarily to hospitals, wound-care clinics, and the U.S. Department of Veterans Affairs (VA). It operates in the biotechnology and medical device space, and its main focus is on hard-to-heal wounds like diabetic ulcers and surgical wounds.

Nuo makes money by selling single-use kits that go along with its Aurix device, creating a recurring consumables revenue stream. It operates almost entirely in the United States, and its relationship with the VA provides a somewhat stable customer base. However, the company is very small, consistently loses money, and faces significant risk from limited commercial adoption, reimbursement coverage challenges, and competition from larger wound-care companies with far greater resources.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+168.8% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+37.1% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

58.2%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~1 months

$263,827 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Revenue accelerating

Nuo Therapeutics grew revenue 169% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

65.3%

Premium pricing power — 65.3% gross margin

Operating Margin

-34.3%

Losing money on operations — -34.3%

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+155.8%

Fast-growing sales (155.8% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-41.1%

Burning cash (-41.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial